Market Overview

What's Going On With Aralez Pharmaceuticals?

What's Going On With Aralez Pharmaceuticals?

Shares of Aralez Pharmaceuticals Inc (NASDAQ: ARLZ), a specialty pharmaceutical company, fell nearly 11 percent on Wednesday ahead of an expected U.S. Food and Drug Administration ruling for its Yosparala therapy.

Aralez's therapy helps prevent cardiovascular disease in patients at-risk for aspirin induced ulcers. Some experts suggested it's "highly likely" Yosprala would be approved by the FDA by the September 14 PDUFA date, which would pave a path towards a commercial launch in the fourth quarter of 2016.

Shares of Aralez were trading lower by more than 12 percent in Thursday's pre-market trading session as no update was provided by the company. However, the stock was halted around 7:10 a.m. ET at $4.80 per share pending news.

Twitter Inc (NYSE: TWTR) users were mixed on the lack of data as some investors are bracing for potential bad news while others are optimistic.



Related Articles (ARLZ)

View Comments and Join the Discussion!

Posted-In: PDUFA Date YosparalaBiotech News Health Care FDA Movers General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at